November 11, 2016Open Access

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This review includes a large number of patients with type 2 diabetes and found that SGLT2-i reduces HbA1c with a notable increased risk in non-serious adverse events. The analyses may overestimate the intervention benefit due bias.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Storgaard et al. (Fri,) studied this question.

synapsesocial.com/papers/69dab353615cc0c8eaa3ceea https://doi.org/https://doi.org/10.1371/journal.pone.0166125

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes2003 · 4,405 citations
2Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials2013 · 84 citations
3Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes2015 · 150 citations
4Effect of canagliflozin on liver function tests in patients with type 2 diabetes2015 · 126 citations
5Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone2014 · 253 citations

Me gusta

Guardar

Ver artículo completo